Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Entry into a Material Definitive Agreement
28 Feb 24
8-K
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
8-K
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
7 Nov 23
8-K
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
31 Oct 23
8-K
Regulation FD Disclosure
12 Sep 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
8-K
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8 Aug 23
8-K
Results of Operations and Financial Condition
27 Jul 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
28 Feb 24
POS AM
Prospectus update (post-effective amendment)
28 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 24
S-8
Registration of securities for employees
12 Jan 24
S-3ASR
Automatic shelf registration
9 May 23
S-8
Registration of securities for employees
28 Feb 23
424B5
Prospectus supplement for primary offering
7 Nov 22
424B5
Prospectus supplement for primary offering
28 Feb 22
S-8
Registration of securities for employees
28 Feb 22
S-3
Shelf registration
9 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
18 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
20 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
Other
EFFECT
Notice of effectiveness
19 Nov 21
CORRESP
Correspondence with SEC
16 Nov 21
UPLOAD
Letter from SEC
15 Nov 21
EFFECT
Notice of effectiveness
18 May 20
CORRESP
Correspondence with SEC
13 May 20
UPLOAD
Letter from SEC
13 May 20
CT ORDER
Confidential treatment order
17 Mar 20
EFFECT
Notice of effectiveness
17 Sep 18
CORRESP
Correspondence with SEC
12 Sep 18
CORRESP
Correspondence with SEC
16 Jul 18
Ownership
4/A
Ashish Mandelia
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G
BALYASNY ASSET MANAGEMENT L.P.
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
Anna Protopapas
17 Jan 24